Browse News
Filter News
Found 21 articles
-
Oxford Biomedica Appoints Dr. Michael Hayden as Non-Executive Director
7/15/2021
Oxford Biomedica plc, a leading gene and cell therapy group, is pleased to announce that Dr. Michael Hayden has been appointed to the Group’s Board as a Non-Executive Director
-
Prilenia: FDA Grants Orphan Drug Designation for pridopidine for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
7/12/2021
FDA Grants Orphan Drug Designation is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for pridopidine for the treatment of ALS.
-
Prilenia’s Phase 3 Huntington’s Disease Clinical Trial Achieves 50% Enrollment
7/8/2021
Prilenia’s global phase 3 trial in Huntington’s Disease (PROOF-HD) is ahead of schedule after enrolling 50% (240) of target 480 participants
-
Prilenia receives positive EMA opinion on Orphan Drug Designation for pridopidine in ALS
6/29/2021
Prilenia Therapeutics B.V., a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, received a positive opinion on European Orphan Drug Designation for pridopidine in Amyotrophic lateral sclerosis (ALS).
-
Incisive Genetics Announces Formation Of Scientific Advisory Board And Appointment Of Dr. Michael R. Hayden As Chairperson
6/28/2021
Incisive Genetics Inc., a privately held biotech company specializing in non-viral delivery methods for targeted gene therapies, announced the formation of its Scientific Advisory Board and the appointment of Dr. Michael R. Hayden as chairperson.
-
Besides providing a sense of hope for children with this devastating disease, this research could offer another clue toward unlocking the mystery behind other forms of ALS.
-
A platform trial is also efficient in that it enables the investigators to share placebo information.
-
Prilenia Achieves 25% Enrollment in its Phase 3 HD Trial and Appoints Dr. Goldberg as CSO
5/13/2021
Prilenia’s global phase 3 trial in Huntington’s Disease (PROOF-HD) has enrolled 120 patients on schedule reaching 25% of its target PROOF-HD is the most advanced clinical trial in HD assessing impact on clinical progression
-
Lisa Stockman Mauriello was diagnosed with ALS in January and is seeking access to Biogen’s tofersen (BIIB067) through the Right to Try Act. Her case has reinvigorated the ALS community and its fight for expanded access to investigational therapies for this cruel, always fatal disease.
-
Prilenia Enrolls First Subject in Europe in its PROOF-HD Phase 3 Clinical Trial for Huntington’s Disease
1/28/2021
The trial is designed to replicate previous findings of pridopidine demonstrating maintenance of functional capacity in early HD patients and could lead to the registration of pridopidine
-
Prilenia Announces First Patient Enrolled for Pridopidine Phase 2/3 Platform Trial for ALS
1/8/2021
Pridopidine was chosen in global competition as one of the top drug candidates to participate in the first ever ALS Platform Trial led by the Healey Center at Massachusetts General Hospital This trial is the second late-stage clinical trial in neurodegenerative disorders with pridopidine, in addition to the global Phase 3 trial in Huntington’s disease
-
Investors in the fund include a variety of existing and new limited partners, both groups made up of specialized institutional and corporate investors.
-
Forbion secures EUR 460 million for oversubscribed fifth fund
12/8/2020
Follows very successful 2020, with five major exits/listings: Promedior, KaNDy, Inflazome, Enterprise Therapeutics and Dyne Therapeutics
-
Prilenia Enrolls First Patients Into its PROOF-HD Phase 3 Clinical Trial for Huntington’s Disease in the United States
10/27/2020
PROOF-HD is designed to replicate previous findings of pridopidine demonstrating maintenance of functional capacity in early Huntington’s Disease patients
-
Clinical Catch-Up: September 14-18
9/21/2020
It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies. -
Henk Schuring Joins Prilenia as Chief Regulatory and Commercialization Officer
9/10/2020
Prilenia Therapeutics B.V., a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, announces the appointment of Henk Schuring as Chief Regulatory and Commercialization Officer.
-
Forbion, a European life sciences venture capital firm, announced today that it had closed its Forbion Growth Opportunities Fund at $208 million.
-
Prilenia Therapeutics Raises $62.5m to Fund Late Stage Trials in HD and ALS
6/3/2020
Prilenia Therapeutics B.V., a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, announces that is has raised $62.5M in a Series A financing round to launch the Company’s planned HD and ALS late-stage clinical trials. The funding round was led by Forbion and included new investors, Morningside Venture Investments
-
Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety
3/31/2020
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety.
-
Dr. Michael Hayden Joins AbCellera’s Board of Directors
10/31/2019
AbCellera, a leader in therapeutic antibody discovery from natural immune systems, has appointed Dr. Michael Hayden to its Board of Directors.